Valinor Discovery

While applying machine learning to clinical drug development is a highly relevant and potentially impactful concept, the submission contains severe red flags. The claims regarding audience reach ('everyone') and traction ('most people have used my product') are completely unrealistic for a specialized B2B biotech platform. The severe lack of verifiable data and extremely poor response quality result in a low score consistent with minimal verifiable traction.